Skip to main content

Advertisement

SpringerLink
Log in

Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease

  • Original Article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is the most common neurodegenerative disorder after alzheimer’s disease. Neuroinflammation and oxidative damage are implicated to be responsible for the pathogenesis of neurodegenerative diseases. However, there are a few studies showing the changes in the biomarkers for neuroinflammation and oxidative damage in neurodegenerative diseases. In our study we aimed to examine the role of the molecules that are involved in oxidative stress and inflammation in PD patients taking l-dopa treatment. Oxidized-LDL (ox-LDL), high-sensitivity C-reactive protein (hs-CRP) and the soluble intracellular adhesion molecule (ICAM) were chosen as biomarkers for systemic inflammation and oxidative damage. The patients were classified according to the Hoehn-Yahr staging system. Forty-five idiopathic l-dopa-given PD patients and 25 age-matched healthy controls were examined. Plasma ox-LDL and ICAM levels were significantly higher in PD patients when compared with controls (p < 0.001 and p < 0.05, respectively). PD patients at all stages had significantly higher plasma ox-LDL levels than controls (p < 0.001). Plasma ICAM levels at stage 1 and 2 and CRP levels at stage 2 patients were significantly higher than controls (p < 0.05, p < 0.05, and p < 0.01, respectively). We insist that further studies have to be conducted to establish neuroinflammation and oxidative damage in PD. Establishing the roles of these pathological processes in PD might be the key to effective therapy at an early stage by antioxidants and/or anti-inflammatory drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson’s disease. Adv Neurol 45:19–34

    PubMed  CAS  Google Scholar 

  2. Hirsch EC (1993) Does oxidative stress participate in nerve cell death in Parkinson’s disease? Eur Neurol 33:52–59

    Article  PubMed  Google Scholar 

  3. Fahn S, Sulzer D (2004) Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx. 1:139–154

    Article  PubMed  Google Scholar 

  4. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease. Evidence supporting it. Ann. Neurol. 32:804–812

    CAS  Google Scholar 

  5. Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 53:S49–S58

    Article  PubMed  CAS  Google Scholar 

  6. Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp Neurol 193:279–290

    Article  PubMed  CAS  Google Scholar 

  7. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H et al (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150

    Article  PubMed  CAS  Google Scholar 

  8. Orr CF, Rowe DB, Halliday GM (2002) An inflammatory review of Parkinson’s disease. Prog Neurobiol 68:325–340

    Article  PubMed  CAS  Google Scholar 

  9. Wu SS, Frucht SJ (2005) Treatment of Parkinson’s disease: what’s on the horizon? CNS Drugs 19(9):723–743

    Article  PubMed  CAS  Google Scholar 

  10. Allain H, Bentué-Ferrer D, Akwa Y (2008) Disease-modifying drugs and Parkinson’s disease. Prog Neurobiol 84:25–39

    Article  PubMed  CAS  Google Scholar 

  11. Salvayre R, Auge N, Benoist H, Negre-Salvayre A (2002) Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta 1585(2–3):213–221

    PubMed  CAS  Google Scholar 

  12. Song IU, Chung SW, Kim JS, Lee KS (2011) Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease. Neurol Sci. 32(1):31–34

    Article  PubMed  Google Scholar 

  13. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL (2006) Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197(2):275–283

    Article  PubMed  CAS  Google Scholar 

  14. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S (2003) Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 108:2041–2048

    Article  Google Scholar 

  15. Inoue N (2006) Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 6(4):227–231

    PubMed  CAS  Google Scholar 

  16. Weber C, Fraemohs L, Dejana E (2007) The role of functional adhesion molecules in vascular inflammation. Nat Rev Immunol 7(6):467–477

    Article  PubMed  CAS  Google Scholar 

  17. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23(4):474–483

    Article  PubMed  Google Scholar 

  18. Hermanowicz N (2007) Drug therapy for Parkinson’s disease. Semin Neurol 27(2):97–105

    Article  PubMed  Google Scholar 

  19. Gao HM, Liu B, Zhang W, Hong JS (2003) Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci 24(8):395–401

    Article  PubMed  CAS  Google Scholar 

  20. Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp Neurol 193:279–290

    Article  PubMed  CAS  Google Scholar 

  21. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R (2007) Inflammation in Parkinson’s diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 13(18):1925–1928

    Article  PubMed  CAS  Google Scholar 

  22. Schroeter H, Williams RJ, Versen L, Rice-Evans CA (2000) Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radic Biol Med 29(12):1222–1233

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Research Found of the Istanbul University (UDP-3809/22052009).

Author information

Authors and Affiliations

  1. Department of Biochemistry, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Gülnur Andican, Dildar Konukoglu, Sinem Firtiına & Gülden Burcak

  2. Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University, Taskisla cad., No 3, Da 21, Sisli, Istanbul, Turkey

    Melda Bozluolcay

  3. Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Kemal Bayülkem

Authors
  1. Gülnur Andican
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dildar Konukoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melda Bozluolcay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kemal Bayülkem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sinem Firtiına
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gülden Burcak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melda Bozluolcay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andican, G., Konukoglu, D., Bozluolcay, M. et al. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease. Acta Neurol Belg 112, 155–159 (2012). https://doi.org/10.1007/s13760-012-0015-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-012-0015-3

Keywords

Search

Navigation